News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,065 Results
Type
Article (39739)
Company Profile (248)
Press Release (660078)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204188)
Career Advice (2008)
Deals (35421)
Drug Delivery (95)
Drug Development (81053)
Employer Resources (172)
FDA (16189)
Job Trends (14864)
News (345230)
Policy (32547)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49444)
ALS (95)
Alzheimer's disease (1384)
Antibody-drug conjugate (ADC) (132)
Approvals (16187)
Artificial intelligence (265)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (292)
Cancer (2322)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (156)
Cell therapy (439)
Cervical cancer (20)
Clinical research (66092)
Collaboration (857)
Company closure (2)
Compensation (569)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (251)
Cystic fibrosis (102)
Data (2337)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6382)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (97)
Earnings (87072)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112670)
Executive appointments (745)
FDA (17570)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (774)
Gene editing (109)
Generative AI (20)
Gene therapy (315)
GLP-1 (719)
Government (4432)
Grass and pollen (4)
Guidances (162)
Healthcare (18820)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (143)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (98)
Interviews (312)
IPO (16530)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (325)
Lymphoma (157)
Machine learning (9)
Management (58)
Manufacturing (329)
MASH (77)
Medical device (13385)
Medtech (13390)
Mergers & acquisitions (19468)
Metabolic disorders (708)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (94)
Neuropsychiatric disorders (27)
Neuroscience (1943)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (40)
Obesity (371)
Opinion (205)
Ovarian cancer (81)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (154)
Partnered (22)
Patents (245)
Patient recruitment (116)
Peanut (46)
People (57351)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20593)
Phase II (29111)
Phase III (21676)
Pipeline (1385)
Policy (147)
Postmarket research (2563)
Preclinical (8763)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (385)
Real estate (5907)
Recruiting (65)
Regulatory (22328)
Reports (48)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (132)
Series B (91)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (51)
The Weekly (30)
Vaccines (699)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (129)
Last 7 days (975)
Last 30 days (3228)
Last 365 days (32472)
2025 (11962)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37884)
Australia (6193)
California (6430)
Canada (2069)
China (539)
Colorado (274)
Connecticut (281)
Delaware (158)
Europe (81415)
Florida (957)
Georgia (216)
Idaho (57)
Illinois (547)
India (25)
Indiana (323)
Iowa (11)
Japan (173)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (923)
Massachusetts (4780)
Michigan (226)
Minnesota (405)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1798)
New Mexico (28)
New York (1809)
North Carolina (992)
North Dakota (8)
Northern California (2838)
Ohio (210)
Oklahoma (14)
Oregon (34)
Pennsylvania (1430)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (26)
South Dakota (1)
Southern California (2415)
Tennessee (106)
Texas (954)
United States (24080)
Utah (188)
Virginia (152)
Washington D.C. (64)
Washington State (566)
West Virginia (3)
Wisconsin (57)
700,065 Results for "exicure inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Exicure, Inc. Reports Full Year 2024 Financial Results
March 18, 2025
·
7 min read
Press Releases
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
April 14, 2025
·
1 min read
Press Releases
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
March 14, 2025
·
2 min read
Press Releases
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
April 11, 2025
·
1 min read
Press Releases
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
January 23, 2025
·
5 min read
Deals
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”).
May 23, 2024
·
3 min read
Press Releases
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
December 26, 2024
·
4 min read
BioMidwest
Exicure, Inc. Reports First Quarter 2024 Financial Results
Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
June 17, 2024
·
6 min read
Business
Exicure, Inc. Reports Full Year 2023 Financial Results
Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
June 6, 2024
·
6 min read
Business
Exicure, Inc. Reports Third Quarter 2023 Financial Results
Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
May 16, 2024
·
6 min read
1 of 70,007
Next
